HemaSphere (Aug 2023)
P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
- Steven Le Gouill,
- Franck Morschhauser,
- David Chiron,
- Kamal Bouabdallah,
- Guillaume Cartron,
- Rene Olivier Casasnovas,
- Caroline Milin,
- Charles Herbaux,
- Emmanuelle Tchernonog,
- Cedric Rossi,
- Simon Rule,
- Thomas Gastinne,
- Mary Callanan,
- Benoit Tessoulin
Affiliations
- Steven Le Gouill
- 1 Curie, Paris, France
- Franck Morschhauser
- 2 Lille University Hospital, Lille, France
- David Chiron
- 3 CRCI²NA, Nantes, France
- Kamal Bouabdallah
- 4 Bordeaux university Hospital, Bordeaux, France
- Guillaume Cartron
- 5 Montpellier University Hospital, Montpellier, France
- Rene Olivier Casasnovas
- 6 Dijon University Hospital, Dijon, France
- Caroline Milin
- 7 Nantes University Hospital, Nantes, France
- Charles Herbaux
- 5 Montpellier University Hospital, Montpellier, France
- Emmanuelle Tchernonog
- 5 Montpellier University Hospital, Montpellier, France
- Cedric Rossi
- 6 Dijon University Hospital, Dijon, France
- Simon Rule
- 8 Astrazeneca Canada, Mississauga, Canada
- Thomas Gastinne
- 9 Nantes University Hospital, Hematology, Nantes, France
- Mary Callanan
- 6 Dijon University Hospital, Dijon, France
- Benoit Tessoulin
- 7 Nantes University Hospital, Nantes, France
- DOI
- https://doi.org/10.1097/01.HS9.0000971256.60488.02
- Journal volume & issue
-
Vol. 7
p. e6048802
Abstract
No abstracts available.